HERON THERAPEUTICS, INC. /DE/ Financials
Quarterly XBRL submissions from SEC 10-K and 10-Q filings.
Income Statement (Last 8 Quarters)
(3)| Period | Revenue | YoY % | Net Income | YoY % | Operating Income | EPS |
|---|---|---|---|---|---|---|
| Q3 FY202510-Q · 2025-09-30 | $38.2M | — | -$17.5M | — | -$4.1M | -$0.10 |
| Q2 FY202510-Q · 2025-06-30 | $2.5M | — | -$2.4M | — | -$1.6M | -$0.02 |
| Q1 FY202510-Q · 2025-03-31 | $2.3M | — | $2.6M | — | $3.2M | $0.01 |
Balance Sheet
| Period | Total Assets | Total Liabilities | Cash & Equivalents | Shareholders Equity |
|---|---|---|---|---|
| Q3 FY202510-Q | $248.9M | $234.1M | $43.1M | $14.9M |
| Q2 FY202510-Q | $232.1M | $259.3M | $16.5M | $1.5M |
| Q1 FY202510-Q | $235.8M | $264.2M | $19.3M | $1.9B |
Cash Flow Highlights
| Period | Operating Income | Net Income | Gross Profit | Shares Outstanding |
|---|---|---|---|---|
| Q3 FY202510-Q | -$4.1M | -$17.5M | $26.3M | — |
| Q2 FY202510-Q | -$1.6M | -$2.4M | $27.3M | — |
| Q1 FY202510-Q | $3.2M | $2.6M | $30.4M | — |
Filings
(4)Methodology
Every figure on this page is pulled directly from HERON THERAPEUTICS, INC. /DE/'s own XBRL submissions to the U.S. Securities and Exchange Commission. XBRL is the standardized tagging format the SEC requires for line items in 10-K and 10-Q filings, which means revenue, net income, and balance-sheet entries are reported by the company itself — not estimated by us.
Cayman Journal reconciles preferred GAAP tags (for example, Revenues, RevenueFromContractWithCustomerExcludingAssessedTax) and normalizes them so quarter-over-quarter comparability is preserved. Our automated ingestion runs nightly; markets editors spot-check flagged anomalies before they appear on the public hub. Where a tag is missing for a given period, we surface an em dash rather than impute a value.
Source documents are linked under Filings above and point to the original EDGAR submission index. Errors should be reported to [email protected].